New horizons in clinical chemistry and diagnosis are opened up by the Reflotron bench-top Analyser. In just 2-3 minutes parameters can be measured directly from 32ul of whole blood — EDTA, Heparin or Capillary.

Reflotron's entirely automatic operation coupled with its speed and the complete absence of any hazardous sample preparation makes it ideal for use in a STAT laboratory, with extremely bio-hazardous samples, isolation laboratories, or wherever results are needed on the spot.

*Innovative: awarded the 1985 German industrial prize for innovation

Current Parameters
Glucose, Urea, Y-GT,
Haemoglobin, Cholesterol,
Triglycerides, AST, ALT,
Uric Acid, Bilirubin,
Amylase

BOEHRINGER MANNHEIM N.Z. LIMITED
**Ionetics EA II**

**Stat Analysis**

**The Electrolyte Analyzer II**

<table>
<thead>
<tr>
<th>Analyzer</th>
<th>Potassium</th>
<th>Sodium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resolution:</td>
<td>0.1 mmol/L</td>
<td>1 mmol/L</td>
</tr>
<tr>
<td>Linear range:</td>
<td>0.2 to 20</td>
<td>100 to 200</td>
</tr>
<tr>
<td>Repeatability:</td>
<td>±0.1</td>
<td>±1</td>
</tr>
<tr>
<td>Sample size:</td>
<td>0.6 ml or larger (whole blood, serum or plasma)</td>
<td></td>
</tr>
<tr>
<td>Read out time:</td>
<td>15 seconds</td>
<td></td>
</tr>
</tbody>
</table>
ONLY 1 ML OF BLOOD IS REQUIRED FOR THE ESR USING VES-TEC AND VACU-TEC TUBES!

VES-TEC and VACU-TEC tubes are inserted into the VES-MATIC instrument exactly as they arrive from the collection centers or hospital wards, without having to be opened for blood transfer. The VES-MATIC carries out up to 60 ESR determinations simultaneously. The VES-MATIC automatically mixes the samples, measures the level of the sample before and after sedimentation, elaborates and prints the results.

The VES-MATIC eliminates any sample handling, therefore presenting a completely automated method for the ESR determination, and eliminating infection risk for laboratory personnel.

For smaller numbers of determinations, the VES-RACK, which holds up to 20 VES-TEC and/or VACU-TEC tubes, is available.
TABLE OF CONTENTS

Original Articles

Investigation of Lewis Phenotypes in Polynesians:
   Variability in Detection of Lewis Antigens by Monoclonal, Goat and Human Anti-sera.
   S.M. Henry, L.A. Simpson, A.G. Benny, D.G. Woodfield ........................................ 64

Using the Correlation Co-efficient in the Determination of Reference Intervals
   P.L. Hurst .......................... 68

Annual Report .................................................. 69

The Pacific Way .................................................. 79

Institute Business ............................................ 81

Letters to the Editor ........................................... 82

New Products and Services ................................. 82

Subscriptions to the Journal for non-members requiring delivery in New Zealand is $NZ33.00 for 1 year surface mail paid. Single issues are $NZ12.00 surface mail paid.

Subscription to the Journal for non-members requiring delivery overseas is $NZ39.60 for 1 year surface mail paid. All subscriptions except for single issues are due in February.

DIRECTIONS FOR CONTRIBUTORS

From Vol. 36 No. 1 all papers published will be in the form known as "Vancouver Style" or Uniform Requirements for Manuscripts submitted to Biomedical Journals. Full details may be found in the New Zealand Journal of Medical Laboratory Technology, Vo. 42 No. 2, page 54 to 60 or from the Editor.

Intending contributors should submit their material to the Editor, D. Dixon-Mclver, Biochemistry Laboratory, National Women's Hospital, Auckland, New Zealand, or The Editor, P.O. Box 35-276, Auckland 10, New Zealand. Acceptance is at the discretion of the Editor, and no undertaking is given that any article will be published in a particular issue. The copy deadline for each issue is the first of the month prior to the month of publication.

ADVERTISER INQUIRIES

Inquiries regarding advertising rates and copy or blocks for advertising should be addressed to the Advertising Manager, Trish Reilly, 48 Towai St, St Heliers, Auckland 5, Phone 555-057.

DATES OF PUBLICATION

The months of publication for 1989 are March, May, August and November.

This Journal is abstracted by: Biological Abstracts, Chemical Abstracts, Cumulative Index to Nursing & Allied Health Literature, Current Clinical Chemistry, Hospital Abstracts, Institut nauchnol informatsii.

Contributions to the Journal do not necessarily reflect the views of the Editor, nor the policy of the Council of the Institute.
Investigation of Lewis Phenotypes in Polynesians: Variability in Detection of Lewis Antigens by Monoclonal, Goat and Human Anti-sera.

Department of Transfusion Medicine, Auckland Regional Blood Centre, Auckland Hospital, Auckland, New Zealand.

Address for Correspondence: S.M. Henry, ANZIMLT, Auckland Regional Blood Centre, Auckland Hospital, Park Road, Auckland 1, New Zealand.

Abstract
Commercially available monoclonal, goat and human Lewis antisera (Le\(^a\), Le\(^b\)) were evaluated for red cell phenotyping of Polynesians. These antisera did not always give concordant phenotypes when tested in parallel. No single anti-Le\(^b\) reagent could detect all the Le\(^b\) antigens defined by either of the three antisera used, suggesting that no single antisera was capable of accurate Lewis phenotyping of Polynesians. Monoclonal anti-Le\(^b\) failed to react with many of the Le(a+b+) samples although it did consistently detect the Le\(^b\) antigen in Le(a-b+) samples indicating a clear specificity for this antigen. Score results indicated that the non detection of Le\(^b\) in Le(a+b+) samples could not entirely be attributed to a lower titre of the monoclonal anti-Le\(^b\). These results suggest there may be an Le\(^b\) epitope common to all Polynesian Le(a-b+) individuals but not common to all Le(a+b+) individuals.

It is proposed that some Polynesians have an Le\(^b\) antigen with a structural difference in the recognition area, a difference that is reactive (at least partially) with polyclonal sera but not recognised by monoclonal sera.

Key words
Lewis antigen, Lewis antisera.

Introduction
Most antibodies in man and animals are heterogeneous mixtures of molecules with similar but not identical specificities. These polyclonal antibodies probably react with many different epitopes on the same antigen. In contrast monoclonal antibodies by the nature of their preparation will recognise only a single epitope of the multiple epitopes carried on some blood group antigens. With the introduction of monoclonal antibodies into routine immunohaematology several different monoclonal antibodies have revealed variance in their ability to detect antigens defined by polyclonal sera. These include a monoclonal anti-M that undilutes, reacts with M negative red cells [1], the detection rate of weak ABO variants [2] and recognition of different epitopes of the Gerbich antigen [3].

Lewis antigens are well defined oligosaccharide structures built on common precursor chains and involving the interaction of the Le and Se genes [4]. Detection of these antigens is generally made using saline reactive human or goat reagents, and more recently monoclonal reagents.

In recent years, the Lewis system has become increasingly important in the field of renal transplantation [5-7] and colonic carcinoma [8]. As the incidence of renal disease is high in Polynesians [9,10], and because the frequency of Lewis phenotypes in Polynesians appear to differ from those of Europeans [11] a survey was undertaken to establish the reliability of monoclonal, goat and human sera in determining Polynesian Lewis phenotypes.

Materials and Methods

Samples
Blood samples were obtained over a period of 3 months from Polynesian (Pacific Islanders and Maoris) blood donors resident in the North Island, New Zealand. All Polynesians were first identified by sight and only those predominantly of polynesian ancestry were accepted for this study. The ethnic distribution for the 108 samples was 57 Maoris, 35 Samoans, 7 Cook Islanders, 5 Tongans and 4 Niueans. Samples for controls were collected from 85 predominantly non group O European blood donors. The ABO distribution for these control samples was 13 group O, 46 group A, 21 group B and 5 group AB.

Approximately seven millilitres of venous blood was collected into 1mL of citrate phosphate dextrose anticoagulant (Becton Dickson, Rutherford, NJ). Blood samples were stored at 4°C and phenotyped within 3 days of collection.

Saliva was obtained from 102 of these Polynesians, processed and tested as described elsewhere [12].

Antisera
Mouse monoclonal anti-Le\(^a\) (111037), anti-Le\(^b\) (113057) and human anti-Le\(^a\) (111057) and anti-Le\(^b\) (111047) were supplied by Biotest (Frankfurt, WG). Anti-Le\(^a\) (LA346A1) and anti-Le\(^b\) (LB544A2) of goat origin were supplied by Ortho Diagnostic Systems (Raritan, NJ).

Human ABO antisera were supplied by Biological Laboratoried Ltd., Auckland, NZ.

All testing was carried out by the manufacturers recommended methods and appropriate controls were used at all stages. Agglutination reactions were read with a 10X magnification eyepiece and scored by the numerical system of Marsh [13] (12 = +++++, 10 = +++, 8 = ++, 5 = +, 3 ±, 2 = w, 0 = no agglutination).

Anti-Le\(^b\) inhibition Study
The ability of Ortho goat anti-Le\(^b\) (LB5454A3) to detect the Le(a+b+) phenotype after inhibition of anti-Le\(^b\)\(^n\) activity with group O Le(a-b-) secretor saliva [14] was tested. Five hundred microlitres of saliva from a Caucasian group O Le(a-b-) secretor was added to 2mL aliquot of anti-Le\(^b\) (Test). A dilution control using 500 mL of saline (group O Le(a-b-) non-secretor saliva was not available) added to a second 2 mL aliquot of anti-Le\(^b\) (Control) was tested in parallel. The treated anti-Le\(^b\) reagents were incubated at RT for 1 hour before they were used.

Table 1: Distribution of concordant and discordant Lewis phenotypes using human, goat and monoclonal sera.

<table>
<thead>
<tr>
<th>Race</th>
<th>No</th>
<th>Concordant</th>
<th>Discordant</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>a+b</td>
<td>a-b</td>
<td>a-b</td>
</tr>
<tr>
<td>Maori</td>
<td>57</td>
<td>12</td>
<td>35</td>
</tr>
<tr>
<td>Samoan</td>
<td>35</td>
<td>9</td>
<td>15</td>
</tr>
<tr>
<td>Cook Isl</td>
<td>7</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Tongan</td>
<td>5</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Niuean</td>
<td>4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Controls (Caucasian)</td>
<td>85</td>
<td>22</td>
<td>52</td>
</tr>
</tbody>
</table>

1 ???: — Abbreviation used when phenotypes obtained using the three different antisera were not in agreement.
Table II. Polynesian and control phenotype discrepancies

<table>
<thead>
<tr>
<th>Number/Group</th>
<th>Lewis phenotypes derived from results</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mono</td>
</tr>
<tr>
<td>Polynesians</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>3</td>
</tr>
<tr>
<td>Controls</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>0</td>
</tr>
</tbody>
</table>

n = number tested. Mono = monoclonal antiserum; Goat = goat antiserum; Human = human antiserum.

Thirteen of 14 goat sera defined Le(a+b+) and 7 random Le(a-b+) Polynesian samples from this survey as well as 5 Caucasian Le(a-b+) control samples were recovered from liquid nitrogen. All samples were deglycerolised, washed 6 times and prepared as 5% cell suspensions in saline. Twenty microlitres of each suspension was added to two glass tubes, then 50 µL of the appropriate antiserum added. After 30 minutes incubation at RT, tubes were centrifuged and the agglutinations graded.

Results

Samples from 108 random Polynesians and 85 Caucasian controls were tested with three Lewis antisera of different origin. The distributions of the Lewis phenotypes using each of these sera is summarised in Table I along with the discordant results, recorded as the Le(????) phenotype. Discordant results are those where one or more of the three antisera gave a different phenotypic interpretation.

The results of the 17 Polynesian and 6 control samples that gave serological discrepancies are summarised in Table II. Goat antiserum detected 5 Le(a-b+) reactions in concordance with human sera that were undetected with monoclonal sera and

Table III. Number of weak reactions in Le(a-b+) and Le(a-b+).

<table>
<thead>
<tr>
<th>Polysery</th>
<th>Number of weak reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n Mono</td>
</tr>
<tr>
<td>Anti-Lea</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>% 4</td>
</tr>
<tr>
<td>Anti-Leb</td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>% 13</td>
</tr>
</tbody>
</table>

weak reactions = score 2-8, n = number tested. Mono = monoclonal antiserum; Goat = goat antiserum; Human = human antiserum.

Table IV. Inhibitory effect of Le(a-b-) secretor saliva on goat anti-Lea

<table>
<thead>
<tr>
<th>Lewis Phenotype</th>
<th>Average Anti-Lea Score</th>
<th>Number of negative results</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Test</td>
<td>Control</td>
</tr>
<tr>
<td>Polynesian</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Le(a-b+)</td>
<td>7</td>
<td>6.3</td>
</tr>
<tr>
<td>Le(a+b+)</td>
<td>13</td>
<td>1.7</td>
</tr>
<tr>
<td>Caucasian</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Le(a-b+)</td>
<td>5</td>
<td>10.0</td>
</tr>
</tbody>
</table>

5 Le(a-b+) reactions undetected by either human or monoclonal sera. Goat antiserum in concordance with monoclonal sera detected 1 Lea and 1 Leb reaction not detected by human sera. Monoclonal antiserum detected 4 Lea and 1 Leb reaction not detected by either human or goat sera. Human sera detected 1 Leb reaction which was undetected by both the goat and monoclonal sera.

Monoclonal anti-Lea detected weak reactions (scores of 3) in 6 of the 17 group B Le(a-b+) controls whereas this reactivity was detected in only one of these samples by human sera, and not detected with the goat sera.

Monoclonal anti-Leb reacted with only 36% (5 of 14) samples defined as Le(a+b+) but with 100% of the samples defined as Le(a-b+) by the goat antiserum.

To allow comparison of reactivity between sera, the results from the Le(a-b+) and Le(a+b+) phenotypes were divided into the number of strong and weak reactions obtained (Table III). Weak reactions were defined as those with a score within the score range of 2-8. Monoclonal anti-Lea detected only 1 weak reaction in 46 samples compared with 16 weak reactions with goat sera and 23 with human sera. Goat anti-Leb detected only 1 weak reaction in 108 samples compared with 12 weak reactions with monoclonal sera and 53 with human sera.

Average Lea reaction scores for the Le(a-b+) samples showed that human anti-Lea reacted marginally weaker against Polynesian Lea antigen than that of the controls (average scores of 8.3 and 9.4 respectively). The more reactive monoclonal and goat sera showed no variation, with similar respective scores of 10.9 and 11.4 for both the Polynesians and controls.

Polyclonal goat anti-Lea was mixed with non-secretor saliva to inhibit anti-Lea reaction [14]. If this activity was present then a reduction in potency of the sera under test would be expected. A dilution control using saliva was tested in parallel (group O Le(a-b-) non-secretor saliva was not available). Eight Le(a-b+) and 1 Le(a+b+) sample failed to react with the saliva treated anti-Lea but were still reactive with the control anti-Lea (Table IV). Two Le(a+b+) samples failed to react with the control anti-Lea, demonstrating that as little as a 20% dilution of anti-Lea can make the antiserum non-reactive.

Discussion

The monoclonal, goat and human Lewis antisera used for phenotyping Polynesians in this study were not in concordance for the determination of Lewis phenotypes. No single antiserum detected all the expected Lea antigens, indicating that no single antiserum was reliable for the determination of Polynesian Lewis phenotypes.

Anti-Leb

The detection of 4 Leb reactions in the Polynesian Le(a-b+) samples by the monoclonal sera (Table II) was not unexpected because of the strong reactivity of this sera. As Le(a-b+) samples are known to have Lea antigen [15] this
detection of Lea is probably related to the strength of the mononclonal sera. This increased sensitivity of monoclonal anti-Lea for Lea antigen has been previously reported [16,17]. It is possible the weak Lea reaction of the group B Le(a+b+) control samples is due to the presence of more Lea antigen or the steric presentation being more favourable to the monoclonal anti-Lea sera. The reaction is unlikely to be due to anti-B contamination as the majority of group B samples tested were negative.

Monoclonal anti-Lea could be considered to be too strong because it detected weak Lea reactions on Le(a+b+) samples whereas human sera could be considered too weak, as it failed to detect an Lea reaction in a Le(a+b-) sample. Anti-Lea

Monoclonal anti-Lea failed to detect the Lea antigen on many of the polyclonal sera defined Le(a+b+) samples. The possibility that this failure was due to reagent potency was examined. However, the human sera which was determined to be the least reactive of the three antisera (Table III) detected 5 Lea reactions in concordance with goat sera, that were not detected by the monoclonal sera (Table II). In addition monoclonal anti-Lea reagent detected one reaction which was undetected by both human and goat anti-Lea.

Using monoclonal antisera the Le(a+b+) phenotype, as defined by goat or human sera is less commonly detected. Unlike previous reports [17,18] that indicate monoclonal anti-Lea is superior to polyclonal sera, the monoclonal anti-Lea used in this study was not as sensitive as the polyclonal sera in detecting the Lea antigen in Polynesians.

Association of the Le(a+b+) phenotype with ABO groups and H antigen reactivity [11,19] appears (at least in part) to be due to reactivity with anti-Lea hi, or a similar H reactive antibody, present in polyclonal anti-Lea (Table IV). Reactivity with this component of polyclonal sera [20] would cause a greater detection rate of a weak Lea antigen expression in H reactive samples. The combined effect of the anti-Lea hi and anti-Lea hi components of polyclonal sera may allow the threshold of agglutination to be achieved with some samples, an effect not possible with monoclonal sera. Some Polynesian red cell samples which typed as Le(a+b-) probably have Lea antigen present but at levels too low to support agglutination. This is supported by the finding that a 20% reduction in the potency of the goat anti-Lea sera resulted in some Lea antigens becoming undetectable.

Comment

The secretor gene which is responsible for the formation of Lea antigen is not a regulator gene but rather a structural gene closely linked to the H gene [21]. The Se gene codes for an alpha-2-L-fucosyl-transferase present in epithelial tissue and able to transform both type-1 and type-2 precursor chains. The Le(a+b+) phenotype may be the result of a change in the normally found equilibrium of the Secretor and Lewis gene coded transferases. Whichever gene is involved the net effect would be a decreased production of type-1-H chains from available precursor chains. Once the type-1 chain has been converted into Lea substance by the action of the Le gene coded transferase, the Se gene coded transferase cannot convert the chain into type-1-H hence lower levels of Lea antigen would result.

Theoretically the Le(a+b+) phenotype could be caused by a more efficient than usual Le gene competing more successfully than the Se gene for type-1 precursor chains; alternatively a less efficient secretor gene could give the same result. The finding of weak secretor phenotypes in Le(a−b−) individuals in a Le(a+b+) Japanese family study [22,23], and by ourselves in Polynesians [12], suggests the presence of a weak secretor gene (Se−).

It would be expected that a Se− gene would cause partial secretion and the red cell Le(a+b+) or Le(a−b−) phenotype. Further evidence to support this hypothesis is provided by our recent findings of salivary substances in almost all Polynesians regardless of their red cell phenotype [12,24]. The amount of genetically independent precursor chains produced and the ability of the red cells to uptake glycosphingolipids, variables not able to be measured in this study, could also be involved in the phenotypic expression of Lewis antigens. We suggest that the failure of anti-Lea antigen on the red cells of some Polynesians may be due to low levels of Lea antigen, and/or epitopical differences in the currently recognised Lea antigen.

Acknowledgements

The authors would like to thank Christine Glavas, Linda Pinder, Walter Wilson and Bill Capper for their help.

References


Using the Correlation Coefficient in the Determination of Reference Intervals

Paul L Hurst

Chemical Pathology Laboratory, Dunedin Hospital

Presented at the 1988 NZACB — NZIMLT Conjoint Conference, Rotorua

Abstract

Reference intervals are critically important for the interpretation of laboratory results. Conventionally, a reference interval for a given test is defined as the central 95% of values observed within a healthy population. There is no reason to believe that this rigid adherence to the central 95% as a means to distinguish ‘normal’ from ‘abnormal’ values is optimal for all tests. Because of this and because the health of the reference population is usually unverifiable (i.e. any given reference population will contain an unknown proportion of sick but asymptomatic subjects), Merkouriou and Dix (Stat Med 1988, 7:377-385) have argued that health should be abandoned as a criterion of reference data. Instead they suggest distinguishing “typical” (normal) from “atypical” (abnormal) values by purely statistical criteria. Typical values are thus defined as those exhibiting a linear relationship on a value versus percentile plot; linearity being assessed by the Pearson product-moment correlation coefficient, r. The general applicability of the method is illustrated with data from both ‘healthy’ and ‘unhealthy’ populations.

Introduction

Although reference intervals are essential for the interpretation of patients’ results, reference information is said to be the weakest data provided by clinical laboratories (1). If you think about this for a moment you will realise this to be so. We go to great lengths to produce accurate and precise test results — very often exceeding clinical requirements — only to have them compared with reference data that is at best uncertain and at worst inappropriate. Many of our reference intervals are compromises, the effects of age, sex, time and/or other variables being largely ignored.

Readers will be familiar with the conventional strategy for determining reference intervals as promulgated by the International Federation of Clinical Chemistry (IFCC)(2) and outlined in Table 1. Difficulties can arise, however, in several of these steps. Let us consider some of them. Firstly, obtaining a population of healthy individuals in numbers sufficient for statistical analysis poses both logistical and ethical problems. Very often laboratories rely on blood donors and/or hospital staff for their reference individuals; two groups that are not necessarily representative of a population for which reference data is being sought. Even if a reference population can be assembled the health of the individuals remains undefined. Such a sample will inevitably contain an unknown number of sick but asymptomatic individuals with common disorders such as cancer, ischemic heart disease and diabetes, and this in turn must lead to uncertainty as to the accuracy of the reference intervals obtained.

Secondly, we must ask the question: is a healthy population appropriate anyway? Consider the often quoted example of patients with suspected myocardial infarction admitted to a coronary-care unit. Their enzyme results will probably be compared with a reference interval derived from a healthy ambulant population when in fact it seems more logical that they should be compared with a reference interval derived from age-matched patients with similar symptoms but who have not experienced myocardial infarction (3).

Thirdly, the width of the reference interval needs to be considered. Conventionally, we have come to accept a reference interval as encompassing the central 95% of observations within a healthy population and biochemists it seems have not considered alternatives but rather they have become obsessed with determining this 95%. The many elegant mathematical procedures advocated to transform skewed distributions to the more manageable gaussian form attest to this. However, notwithstanding the above comments, there is no reason to believe that the constant adherence to the central 95% as a means to distinguish normal from abnormal values is optimal for all tests. Indeed, recent reference creatine kinase data for men gave a 97.5th percentile upper reference limit of 300 U/L which was considered too high if used in the diagnosis of myocardial infarction, (4) and the unsuitability of the 97.5th percentile of plasma cholesterol concentration as an upper reference limit is well known (3, 5). What in fact does this 95% span tell us? Well, all that it does say is that on average 5% (1 in 20) of apparently healthy subjects will have a value outside this range; it says nothing about the probability of an unhealthy subject having a value outside, or for that matter inside, the reference interval.

Because of considerations such as these Merkouriou and Dix(6) have argued that health should be abandoned as a criterion for reference intervals. Instead they suggest that objective statistical criteria should be used to separate “typical” (normal) from “atypical” (abnormal) values. How then do we decide what are typical and atypical values?

Method

Looking at a skewed frequency distribution (characteristic of many biochemical tests) of creatine kinase values in young women (Fig 1, inset), it is not immediately obvious where the typical values lie, or clear as to the position of appropriate reference limits. Such values, though, become conspicuous on a cumulative percentage plot (Fig 1). Notice the conspicuous deviation from linearity in the tails. Values above about the 90th percentile and below about the 3rd percentile are clearly different, that is atypical, from the linear spread of values inbetween. Linearity on the value-percentile plot is thus a natural objective definition for typical behaviour. At this point, it must be stressed that the region of the 90th percentile has no general significance and Merkouriou and Dix are not proposing it as a substitute for the 97.5th percentile. Rather, the region of the 90th percentile is a boundary between typical values specific for the data in Figure 1. As we shall see later, the points of deviation from linearity are not fixed at any given percentile but depend on the shape and content of the frequency distribution. Our goal then is to locate accurately those points of deviation. The authors give the following method.

<table>
<thead>
<tr>
<th>Table 1: IFCC Strategy for Reference Interval Determination.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capture “Healthy” Population</td>
</tr>
<tr>
<td>Determine Distribution</td>
</tr>
<tr>
<td>Reference Values</td>
</tr>
<tr>
<td>Gaussian</td>
</tr>
<tr>
<td>Transform Non-Parametric Percentiles</td>
</tr>
<tr>
<td>Mean ± 2SD</td>
</tr>
<tr>
<td>Non-Gaussian</td>
</tr>
<tr>
<td>Mean ± 2SD</td>
</tr>
</tbody>
</table>
TECHNICAL ASSISTANTS
EXAMINATION COMMITTEE

Members of the Committee are B.T. Edwards (Convener), K. McLoughlin, G. Patridge, J. LeGrice and T. Rollinson.

The 1988 examinations were conducted on 10 and 11 May. There were 98 candidates for the examination with 92 gaining the Certificate of Qualified Assistant. The pass rate was 94% compared with 90% the previous year.

Breakdown of figures are:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Biochemistry</td>
<td>13</td>
<td>13</td>
<td>16</td>
<td>15</td>
</tr>
<tr>
<td>General Certificate</td>
<td>8</td>
<td>7</td>
<td>10</td>
<td>8</td>
</tr>
<tr>
<td>Haematology</td>
<td>20</td>
<td>17</td>
<td>13</td>
<td>9</td>
</tr>
<tr>
<td>Histological Technique</td>
<td>9</td>
<td>9</td>
<td>10</td>
<td>9</td>
</tr>
<tr>
<td>Medical Cytology</td>
<td>4</td>
<td>3</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Medical Microbiology</td>
<td>19</td>
<td>19</td>
<td>26</td>
<td>25</td>
</tr>
<tr>
<td>Mortuary Hygiene &amp; Technique</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Radiodiag &amp; Radiossay Technique</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Immunohaematology</td>
<td>13</td>
<td>13</td>
<td>10</td>
<td>9</td>
</tr>
<tr>
<td>Immunology (Microbiology)</td>
<td>4</td>
<td>4</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Special Certificates</td>
<td>5</td>
<td>4</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Total</td>
<td>98</td>
<td>92</td>
<td>102</td>
<td>92</td>
</tr>
</tbody>
</table>

OVERSEAS AID COMMITTEE

Members of the Committee are E. Norman (Convener), M. Eales and S. Gainford.

The Institute continued to support the P.P.T.C. during the 1988-89 year.

This was mainly in the form of the donation of an appropriate text book to each course graduate and of financial support for the Quality Assurance Programme for Pacific Island Laboratories.

Once again thanks are due to the many individual Institute members who support and assist the P.P.T.C. and especially to Marilyn Eales for her continuing contribution of the Pacific Way section of the Journal.

SAFETY COMMITTEE

Members of the Committee are J. Parker (Convener) and B. Corneere.

With so much occurring in the industrial arena there has been little time to consider safety matters. With the Union forming it is hoped that more attention can be paid to this very important area in the coming year.

AWARDS COMMITTEE

J. Parker (Convener).

Our thanks once again to all those firms who have so generously supported us in the past year. They were as follows:

<table>
<thead>
<tr>
<th>QTA Examination Award Donor</th>
<th>NZ Blood Foundation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Journal Awards</td>
<td>Roche Products (NZ) Ltd</td>
</tr>
<tr>
<td></td>
<td>Travelor Laboratories (NZ) Ltd</td>
</tr>
<tr>
<td>Travel Award</td>
<td>Welcome NZ Ltd.</td>
</tr>
</tbody>
</table>

EDUCATION COMMITTEE

Members of the Committee are J. Parker (Convener), B.T. Edwards and W. Wilson.

This year has been a time of great uncertainty with regards the present and future education of Medical Laboratory Technologists. The decision of the last annual general meeting that the NZIMLT should take responsibility for the Part III examinations was superseded by the decision of the MLTB to request that changing of the regulations be deferred to take effect in the 1990 year. Polytechnics have effectively replaced the NZCS paramedical with a broader based NZCS in module format. At the same time the Auckland Technical Institute has introduced a Diploma course to replace both NZCS and the post NZCS component of the current course. The Hawke Report and the proposals for graduate tax are having effects on both Universities and Polytechnics in terms of funding and provision of new and existing courses. The Under-Secretary of Health undertook to express to the Otago University and to the Education Department ministerial support for our degree proposals, in the Cabinet reshuffle both the Minister and Mr Dunne have moved on and the support of the new Minister is less certain. The Otago University has now been named as the sole school for training Pharmacists in New Zealand from 1990 and this can only strengthen our own case. At present our proposals are 'on the table' with the Otago University who fully intend to pursue the initiative now that the fate of the School of Pharmacy is decided.

PUBLICATIONS COMMITTEE

Members of the Committee are D. Dixon-Mclver (Convener), D. Reilly, W. Wilson and P. Reilly (Advertising Manager).

There were 17 papers proffered for publication (3 Auckland, 3 Dunedin, 3 Wellington, 3 Christchurch, 1 Palmerston North, 1 Blenheim, 1 Rotorua and 1 U.S.A.) of which 15 have been accepted for publication and published. This compares with 14 in 1987, 13 in 1986 and 28 in 1985. The slight upturn in material being proffered is pleasing but it is important that it is maintained.

The editor wishes to record his thanks to Trish Reilly, Maurice Sheppard and the Royal NZ Foundation for the Blind for their continued assistance and support.

MEMBERSHIP COMMITTEE

Members of the Committee are G. Rimmer (Convener), D. Dixon-Mclver and D. Reilly.

Total membership of the Institute has risen and has almost reached the peak of 1985/86. Most of the new members are in the 'Member' category possibly the result of the new legislation which meant that the Institute was deemed to be the Union for this year.
Approximately 2/3 of the membership are taking advantage of the automatic salary deduction to pay their annual subscription. As with any new system there has been a few problems, most of which have now been resolved.

This year 43 Complimentary Members were the last as there were no new additions to this category after March 1988.

With the formation of the N.Z. Medical Laboratory Workers' Union, resulting in probably the biggest change in the Institutes, the retention of membership is an important challenge for the coming year. Please think carefully about the role of and direction of your Institute and remain a part of this new era. Your continued membership is essential to the future of Medical Laboratory Technology as a strong profession.

<table>
<thead>
<tr>
<th>Membership from previous year</th>
<th>1988/89</th>
<th>87/88</th>
<th>86/87</th>
<th>85/86</th>
<th>84/85</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less deletions</td>
<td>1465</td>
<td>1536</td>
<td>1792</td>
<td>1352</td>
<td>1369</td>
</tr>
<tr>
<td>Plus application</td>
<td>1378</td>
<td>1196</td>
<td>1338</td>
<td>1294</td>
<td>1179</td>
</tr>
<tr>
<td>Membership as at 31st March</td>
<td>331</td>
<td>269</td>
<td>198</td>
<td>498</td>
<td>173</td>
</tr>
</tbody>
</table>

**Membership composition:**
- Life Members: 17
- Fellows: 29
- Associates: 781
- Members: 741
- Complimentary Members: 43
- Non-practising Members: 68
- Honorary Members: 30

**FELLOWSHIP COMMITTEE**

*Members of the Committee are J. LeGrice (Convener) K. McLaughlin and H. Potter.*

A discussion document on the proposed revision of the N.Z.I.M.L.T. Fellowship Regulations was presented at the 1988 Conference in Rotorua. The proposals were based on the assumption that the Specialist qualification would no longer be available. However, this assumption proved incorrect and as a result there were no changes to the Fellowship regulations. Some alterations to the regulations are required, not the least of them being an increase in application fee so that the Fellowship system pays its way.

This year the Committee had three applications for Fellowship which covered all three avenues of attainment: thesis, examination and exemption. One of these has been resolved. Mr Rob Seibers was granted Fellowship by exemption on the basis of a higher qualification and the merit of supporting published scientific material.

**INDUSTRIAL RELATIONS COMMITTEE**

*Members of the Committee are P. McLeod (Convener), W. Wilson, D. Dixon-McIver and S. Gainsford.*

The major efforts for the committee during the last year have centered on the establishment of the Medical Laboratory Workers Union and the negotiation of our award.

**N.Z. Medical Laboratory Workers Union**

At the Special General Meeting of the Institute at Rotorua in 1988, the members supported the concept of the establishment of a separate union to handle the industrial matters which the State Sector Act now demands must be available to all State workers. The Institute, it was felt, was not an appropriate body to deal with industrial matters and in future should concentrate on the professional aspects of the organisation.

In March 1989, the inaugural general meeting of the union was held. At this meeting, the draft rules, subscription rate and interim executive were approved. Until one thousand people have joined the union and an application for registration of the union is sought, the Institute will continue to represent its members in all industrial matters.

**Settlement of Award**

The first negotiation round got under way in November 1988, however it became obvious very quickly that it was not the "right time" to settle our award. At that time there had been only a few award settlements in the private sector and the State Services Commission was offering a counterclaim that was verging on the ridiculous.

On March 1, and 2, 1989 we again met with the Commission and proceeded to settle our award. What was achieved is now history and comparing the settlement with other health groups, we feel very pleased with the outcome. This settlement does not expire until July 31st, 1990. In the meantime, all efforts are to be concentrated on establishing the new union and settling an award for the private medical laboratory workers.

I would like to thank all the committee for their untiring efforts and support and to all the members of the Institute who have given us encouragement and support in what is at times an extremely exasperating task. However, I hasten to add, that occasionally this committee does achieve some victories which somehow seem to make it all worthwhile.
NEW ZEALAND INSTITUTE OF MEDICAL LABORATORY TECHNOLOGY INC.
STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 1989

<table>
<thead>
<tr>
<th></th>
<th>1989</th>
<th>1988</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$</td>
<td>$</td>
</tr>
<tr>
<td>ACCUMULATED FUNDS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Balance 1 April 1988</td>
<td>10,538</td>
<td>35,422</td>
</tr>
<tr>
<td>Surplus (deficit) for the year</td>
<td>25,957</td>
<td>(24,884)</td>
</tr>
<tr>
<td>Balance at 31 March 1989</td>
<td>36,495</td>
<td>10,538</td>
</tr>
<tr>
<td>Clinical Laboratory Special Fund (Note 5)</td>
<td></td>
<td>641</td>
</tr>
<tr>
<td>TOTAL FUNDS AS AT 31 MARCH 1989</td>
<td>$36,495</td>
<td>$11,179</td>
</tr>
</tbody>
</table>

Represented by:

CURRENT ASSETS
Cash at bank             | 20,268| 2,852 |
Stock on hand (Note 3)   | 856   | 920   |
Sundry debtors           | 16,142| 24,947|
Subscriptions outstanding|       | 2,007 |
GST                     | 3,408 | 4,593 |
TOTAL CURRENT ASSETS     | 40,674| 35,319|

LESS CURRENT LIABILITIES
Sundry Creditors         | 20,994| 36,741|
Subscriptions in Advance |       | 6,660 |
Examination Fees in Advance | 3,841| 2,272 |
TOTAL CURRENT LIABILITIES| 24,835| 45,673|

NET CURRENT ASSETS (LIABILITIES)
INVESTMENTS (Note 2)     | 15,839| (10,354)|
| 20,000                  |       | 20,000 |

FIXED ASSETS
Typewriters (Note 4)     | 656   | 1,533 |
| $36,495                 |       | $11,179|

Treasurer — D.M. Reilly
President — W. Wilson

The attached notes form part of this statement.
NEW ZEALAND INSTITUTE OF MEDICAL LABORATORY TECHNOLOGY INC. STATEMENT OF INCOME AND EXPENDITURE FOR THE YEAR ENDED 31 MARCH 1989

INCOME FOR THE YEAR WAS DERIVED FROM:

<table>
<thead>
<tr>
<th>Item</th>
<th>1989</th>
<th>1988</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conference surplus (as per statement)</td>
<td>8,960</td>
<td>4,288</td>
</tr>
<tr>
<td>Examination surplus</td>
<td>1,481</td>
<td>521</td>
</tr>
<tr>
<td>Interest received</td>
<td>3,359</td>
<td>6,119</td>
</tr>
<tr>
<td>Miscellaneous income</td>
<td>6,096</td>
<td>2,695</td>
</tr>
<tr>
<td>Subscriptions and levy</td>
<td>90,085</td>
<td>51,186</td>
</tr>
<tr>
<td>Refunds</td>
<td>2,400</td>
<td>-</td>
</tr>
<tr>
<td>Donations</td>
<td>1,200</td>
<td>-</td>
</tr>
<tr>
<td><strong>TOTAL INCOME</strong></td>
<td>113,581</td>
<td>64,809</td>
</tr>
</tbody>
</table>

FROM THIS INCOME THE FOLLOWING EXPENDITURE WAS MET:

<table>
<thead>
<tr>
<th>Item</th>
<th>1989</th>
<th>1988</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accommodation, etc</td>
<td>10,414</td>
<td>9,715</td>
</tr>
<tr>
<td>Accountancy and audit fee</td>
<td>1,524</td>
<td>1,652</td>
</tr>
<tr>
<td>Computer services</td>
<td>9,176</td>
<td>8,404</td>
</tr>
<tr>
<td>Fees — D.S.U., LAMLT and NCCLS</td>
<td>2,455</td>
<td>3,453</td>
</tr>
<tr>
<td>Honoraria, gratuities and prizes</td>
<td>2,050</td>
<td>2,200</td>
</tr>
<tr>
<td>Journal cost (as per statement)</td>
<td>10,277</td>
<td>3,560</td>
</tr>
<tr>
<td>Legal expenses</td>
<td>14,336</td>
<td>2,250</td>
</tr>
<tr>
<td>Post Graduate Education and Pacific Training</td>
<td>1,058</td>
<td>2,551</td>
</tr>
<tr>
<td>Postage and tolls</td>
<td>4,877</td>
<td>5,759</td>
</tr>
<tr>
<td>Printing, stationery and typing</td>
<td>2,203</td>
<td>8,811</td>
</tr>
<tr>
<td>Sundry expenses</td>
<td>1,049</td>
<td>4,349</td>
</tr>
<tr>
<td>Travelling expenses</td>
<td>19,328</td>
<td>22,513</td>
</tr>
<tr>
<td><strong>TOTAL EXPENDITURE FOR YEAR</strong></td>
<td>78,747</td>
<td>75,217</td>
</tr>
<tr>
<td>Consultancy Fees</td>
<td>787,877</td>
<td>10,000</td>
</tr>
<tr>
<td>— Medical Laboratory Trust</td>
<td>877</td>
<td>3,999</td>
</tr>
<tr>
<td><strong>TOTAL EXPENDITURE FOR YEAR</strong></td>
<td>79,624</td>
<td>89,693</td>
</tr>
<tr>
<td>Excess of Income Over Expenditure</td>
<td>33,957</td>
<td>24,884</td>
</tr>
<tr>
<td>Donation to New Zealand Medical Laboratory Science Trust (Note 5)</td>
<td>8,000</td>
<td>-</td>
</tr>
<tr>
<td><strong>Surplus (deficit) for the year</strong></td>
<td>25,957</td>
<td>$(24,884)</td>
</tr>
</tbody>
</table>

The attached notes form part of this Statement.
NEW ZEALAND INSTITUTE OF MEDICAL LABORATORY TECHNOLOGY INC. CONFERENCE ACCOUNT FOR THE YEAR ENDED 31 MARCH 1989

INCOME FOR THE YEAR WAS DERIVED FROM:

<table>
<thead>
<tr>
<th></th>
<th>1989</th>
<th>1988</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration</td>
<td>16,245</td>
<td>8,957</td>
</tr>
<tr>
<td>Trade rentals and advertising</td>
<td>13,471</td>
<td>17,158</td>
</tr>
<tr>
<td>Donations</td>
<td>5,953</td>
<td>3,325</td>
</tr>
<tr>
<td>Social functions and lunches</td>
<td>16,424</td>
<td>10,148</td>
</tr>
<tr>
<td>Bank interest and other income</td>
<td>481</td>
<td>35</td>
</tr>
<tr>
<td>Accommodation</td>
<td>—</td>
<td>3,845</td>
</tr>
<tr>
<td>Other income</td>
<td>1,234</td>
<td>—</td>
</tr>
<tr>
<td><strong>Total Income</strong></td>
<td><strong>53,808</strong></td>
<td><strong>43,468</strong></td>
</tr>
</tbody>
</table>

FROM THIS INCOME THE FOLLOWING EXPENDITURE WAS MET:

<table>
<thead>
<tr>
<th></th>
<th>1989</th>
<th>1988</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel, accommodation and meals</td>
<td>32,967</td>
<td>29,284</td>
</tr>
<tr>
<td>Social function costs</td>
<td>3,261</td>
<td>3,833</td>
</tr>
<tr>
<td>Rentals</td>
<td>1,160</td>
<td>494</td>
</tr>
<tr>
<td>Postage, stationery and administration</td>
<td>3,876</td>
<td>3,889</td>
</tr>
<tr>
<td>Other expenditure</td>
<td>2,396</td>
<td>1,680</td>
</tr>
<tr>
<td><strong>Total Expenditure</strong></td>
<td><strong>43,660</strong></td>
<td><strong>39,180</strong></td>
</tr>
</tbody>
</table>

Which leaves an excess of income over expenditure transferred to the Statement of Income and Expenditure

<table>
<thead>
<tr>
<th></th>
<th>1989</th>
<th>1988</th>
</tr>
</thead>
<tbody>
<tr>
<td>NZACB Share of Profit</td>
<td>1,188</td>
<td>—</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$8,960</strong></td>
<td><strong>$4,288</strong></td>
</tr>
</tbody>
</table>

The attached notes form part of this Statement.

NEW ZEALAND INSTITUTE OF MEDICAL LABORATORY TECHNOLOGY INC. JOURNAL ACCOUNT FOR THE YEAR ENDED 31 MARCH 1989

INCOME FOR THE YEAR WAS DERIVED FROM:

<table>
<thead>
<tr>
<th></th>
<th>1989</th>
<th>1988</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advertising revenue</td>
<td>38,429</td>
<td>40,381</td>
</tr>
<tr>
<td>Subscriptions</td>
<td>1,041</td>
<td>1,426</td>
</tr>
<tr>
<td><strong>Total Income</strong></td>
<td><strong>39,470</strong></td>
<td><strong>41,807</strong></td>
</tr>
</tbody>
</table>

FROM THIS INCOME THE FOLLOWING EXPENDITURE WAS MET:

<table>
<thead>
<tr>
<th></th>
<th>1989</th>
<th>1988</th>
</tr>
</thead>
<tbody>
<tr>
<td>Printing — journal and newsletter</td>
<td>39,370</td>
<td>40,515</td>
</tr>
<tr>
<td>Postage and stationery</td>
<td>4,619</td>
<td>3,722</td>
</tr>
<tr>
<td>Sundry expenses</td>
<td>5,758</td>
<td>1,130</td>
</tr>
<tr>
<td><strong>Total Expenditure</strong></td>
<td><strong>49,747</strong></td>
<td><strong>45,367</strong></td>
</tr>
</tbody>
</table>

Which leaves an excess of expenditure over income transferred to the Statement of Income and Expenditure

<table>
<thead>
<tr>
<th></th>
<th>1989</th>
<th>1988</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total</strong></td>
<td><strong>$10,277</strong></td>
<td><strong>$3,560</strong></td>
</tr>
</tbody>
</table>

The attached notes form part of this Statement.

NEW ZEALAND INSTITUTE OF MEDICAL LABORATORY TECHNOLOGY INC. NOTES TO THE 1989 FINANCIAL STATEMENTS

1. **STATEMENT OF ACCOUNTING POLICIES**

The historical cost basis of accounting has been used in the preparation of the financial statements. Reliance is placed on the fact that the Institute is a going concern. Accrual accounting is used to match expenses and revenues.
Particular accounting policies:

(a) Fixed assets and depreciation.
Depreciation is calculated on a straight line basis to write off the typewriters over their estimated useful lives of 5 years.

(b) Stock is valued at actual cost.
There have been no changes in accounting policies. All policies have been applied on bases consistent with those used in previous years.

2. INVESTMENTS
Debenture stock
General Finance Ltd $20,000 16.5% mature on 21/08/90.

3. STOCK

<table>
<thead>
<tr>
<th>Type</th>
<th>1989</th>
<th>1988</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ties/badges, etc</td>
<td>$856</td>
<td>$920</td>
</tr>
</tbody>
</table>

4. TYPEWRITERS

<table>
<thead>
<tr>
<th>Type</th>
<th>1989</th>
<th>1988</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost</td>
<td>4,385</td>
<td>4,385</td>
</tr>
<tr>
<td>Accumulated depreciation</td>
<td>3,729</td>
<td>2,852</td>
</tr>
<tr>
<td>NET BOOK VALUE</td>
<td>$656</td>
<td>$1,533</td>
</tr>
</tbody>
</table>

5. NEW ZEALAND MEDICAL LABORATORY SCIENCE TRUST
The Council of the New Zealand Institute of Medical Laboratory Technology Inc. approved a donation of $8,000 together with the $641 held in the clinical Laboratory Special Fund to the NZ Medical Laboratory Science Trust.

June 1989

TREASURER'S REPORT
Dennis M. Reilly

The 1988/1989 financial year has ended with a surplus of $25,957. The Institute's income has increased mainly through subscriptions and a significant conference surplus. Council approved that $8,000 from this surplus be passed to the Trust.

A large proportion of members have elected to have their subscriptions deducted from their salaries. Initially there was a few hiccups but now it has settled into a smooth operation, although a significant amount of Treasurer's time is required in processing fortnightly computer print outs and banking cheques. Most Boards have been helpful while others deduct a percentage for their effort.

On the expenditure side the Journal and legal costs stand out as the major increases. The legal costs are virtually all due to the formation of the New Zealand Medical Laboratory Workers Union. This is now separated from the Institute and will not be a continuing expense.

The total expenditure of $79,624 reflects the wide range of activities that we have and if the Institute is to be more involved in examinations such as the 'Specialist' level we will need to maintain our income at a similar level. Consequently Council has suggested that subscriptions be maintained at their present level.

AUDITORS' REPORT TO THE MEMBERS OF THE NEW ZEALAND INSTITUTE OF MEDICAL LABORATORY TECHNOLOGY INC.

Deloitte Haskins + Sells

We have audited the financial statements on pages 1 to 5 in accordance with accepted auditing standards and have carried out such procedures as we considered necessary.

In common with other organisations of a similar nature, control over income prior to its being recorded is limited, and there are no practical audit procedures to determine the effect of this limited control.

Subject to the possible effect of the limited control over income referred to in the preceding paragraph, in our opinion the financial statements give, using the historical cost method, a true and fair view of the financial position of the Institute as at 31 March 1989 and the results of its activities for the year ended on that date.

11 May 1989
MANUKAU CITY, NZ
May 15-18 1990
Tuesday — Friday

Waikiki Sheraton Hotel

Many door prizes including an international roundtrip ticket for two

Renowned speakers schedule include:

Dr Sydney Finegold  Anaerobic microbiology
Dr Ellen Jo Baron  Co-editor of BAILEY & SCOTT'S DIAGNOSTIC MICROBIOLOGY
Dr Lee Hilborne  Recombinant DNA technology
Dr Wayne Grody  Medical genetics/Molecular pathology
Dr Christopher Frings  Laboratory Consultant, Toxicologist
Dr Douglas Triplett  Haematology/Coagulation
Dr Judith Barr  Major contributor in ASMT government activities

Special Topics
Motivation Strategies
Improving Laboratory Utilisation
Government Update and Current Issues

AND MORE . . .

For more information, please complete the following and mail to:

Lucille Holzgang
c/o 98-418 Koanohi St. *3
Aiea, Hawaii 96701

NAME: ________________________________________________
ADDRESS: ________________________________________________
CITY, STATE, ZIP CODE: ____________________________________________

Please send me information on:  □ PROGRAMME  □ TRAVEL PACKAGE
As the range of values extends into the tails of the distribution, the relationship between values and percentiles will deviate from linearity and the magnitude of r will decline. Merkouriou and Dix have chosen 0.9900 as the minimum value of r acceptable because it is the minimum r that permits accurate calculation of regression lines by the classical least-squares method. When symmetrical expansion causes r to recede below the critical value it may be possible to further extend the span of linearity by holding the lower or higher limit fixed and expanding the calculation of r into the opposing tail. In this way the maximum span of linearity is assured.

Results and Discussion

Table 1 details the calculation of the reference interval from the creatinine kinase (CK) distribution in Figure 1. Progressive and symmetrical calculation of r around the median gave acceptable linearity up to 24-78 U/L. Further expansion either symmetrical or asymmetrical caused r to decline below acceptable limits. Thus maximum linearity was obtained between the 2.5th and 95.9th percentiles. For comparison the reference intervals calculated by conventional methods are also listed. In all cases, the conventional methods yielded wider reference intervals. This was to be expected since it is well documented that the conventionally estimated upper reference limit for CK is excessively influenced by extreme values, not only for men as aforementioned but also for women (8). With the exception of cholesterol, medical decision points lower than the 95th-97.5th percentiles have yet to be accepted.

Whilst the associated regression parameters of slope and intercept have no obvious use in the reference interval calculation, the standard error of the estimate (Sy/x), in my opinion, has. Because it can be considered as an average standard deviation in the relationship between x (percentile) and y (analyte value), we can estimate the 95% confidence intervals of the reference interval endpoints as y ± 2 Sy/x. Thus from Table 1 the CK reference interval expressed with confidence intervals parenthetically is 24 (19, 29) — 79 (73, 83) U/L.

Because in this method values are deemed typical or atypical by statistical rather than clinical criteria, the method would seem to have the most potential in the estimation of reference intervals from patients' results. For years biochemists have been attracted to this readily accessible data base, but early methods proposed to extract reference intervals were criticised because they assumed an underlying gaussian distribution of healthy values within the patient population. No such criticism can be levelled at this present method; all that is assumed is that the population distribution is continuous and essentially unimodal.

The data in Figure 2 and Table 3 shows application of this method to a select patient group, viz. all patients for whom angiotensin converting enzyme (ACE) was requested during a twelve month period. Serum ACE is usually requested for...

<table>
<thead>
<tr>
<th>Table 1: Reference Interval from CK Distribution.</th>
</tr>
</thead>
<tbody>
<tr>
<td>CK</td>
</tr>
<tr>
<td>U/L</td>
</tr>
<tr>
<td>48-54</td>
</tr>
<tr>
<td>45-57</td>
</tr>
<tr>
<td>42-63</td>
</tr>
<tr>
<td>39-63</td>
</tr>
<tr>
<td>36-66</td>
</tr>
<tr>
<td>33-69</td>
</tr>
</tbody>
</table>

Method CK reference interval, U/L
r 24-78
parametric 19-96
log-parametric 25-104
percentile 25-107

Beginning near the median (by definition the most typical value), calculate the produce-moment correlation coefficient, r, between values and percentiles from some value slightly below the median to some value slightly above the median. Repeat the calculation by progressively and symmetrically extending the range of values above and below the median.
one of two reasons: (a) the diagnosis and monitoring of sarcoidosis—in which an elevated antihypertensive agent—by selecting the diagnosis and monitoring of hypertension (e.g. captopril) therapy—whence low levels are expected. In Figure 2 the maximum span of linearity occurred between the 5th and 95th percentiles. The corresponding reference interval of 20-83 U/I compares favourably with 24-78 U/I previously established by the nonparametric percentile method from a reference population.

Applying the method to a more heterogeneous patient group was equally successful. Figure 3 shows the frequency distribution of plasma alanine aminopeptidase (AAP) activity in 471 consecutive patients for whom a liver function profile was requested. AAP is an enzyme of diagnostic value similar to gamma-glutamyltransferase. As shown in Table 4, maximum linearity achieved by symmetrical expansion of the calculation of r was 52-107 U/I, but this could be extended down to 42 U/I by holding the upper limit fixed at 107 U/I. The reference interval thus obtained was 42-157 U/I and corresponded to the 2nd-81st percentiles. This was in remarkable agreement with 42-104 U/I calculated from a subset of the same data base according to the strategy of Sinton et al(9), whereby only those AAP values associated with liver function profiles wholly within reference limits were used.

Now I must point out that for reasons of brevity and clarity, in these examples I have used grouped data taken from the frequency distributions (histograms). Ideally, the value-percentile plot should be constructed from data that has been ranked individually. This requires substantially more work but it does give more points on the value-percentile plot which in turn leads to more accurate demarcation between typical and atypical values. Some consideration of the size of the data base is also appropriate here. Merkouriou and Dix suggested that since the method is based on percentiles a minimum of 120 subjects was required. From my own experience with the method I think that is too few. This is especially so with highly skewed patient populations and I recommend at least twice that number. In any case, 120 is now considered manifestly inadequate for the nonparametric percentile method when dealing with skewed distributions(10) up to 700 may be needed.

A purely statistical concept of the reference interval having no connotations of health or disease is clearly unconventional. Typical values may or may not indicate the absence of disease. Clinical follow-up studies must be carried out to validate the reference intervals obtained and correlations between atypical values and disease must be established. It seems to me that a logical extension of such studies would be to collect data from patients with confirmed diagnoses and hence typical and atypical values for that particular pathology. With the days of computer archiving of results upon us this is now possible. It behoves us all to supply more useful information to clinicians. Indeed, Interpretive Reporting has been identified by the IFCC as one area worthy of new endeavour (11).

Table 3: Reference Interval from ACE Distribution.

<table>
<thead>
<tr>
<th>ACE interval</th>
<th>r</th>
<th>Sy/x</th>
</tr>
</thead>
<tbody>
<tr>
<td>U/L</td>
<td></td>
<td></td>
</tr>
<tr>
<td>44-56</td>
<td>0.9982</td>
<td>0.29</td>
</tr>
<tr>
<td>41-59</td>
<td>0.9923</td>
<td>0.20</td>
</tr>
<tr>
<td>38-62</td>
<td>0.9953</td>
<td>0.33</td>
</tr>
<tr>
<td>35-65</td>
<td>0.9964</td>
<td>0.33</td>
</tr>
<tr>
<td>32-71</td>
<td>0.9957</td>
<td>1.21</td>
</tr>
<tr>
<td>29-74</td>
<td>0.9950</td>
<td>1.50</td>
</tr>
</tbody>
</table>

This reference interval: 20-83 U/I (see text)

Table 4: Reference Interval from AAP Distribution.

<table>
<thead>
<tr>
<th>AAP interval</th>
<th>r</th>
<th>Sy/x</th>
</tr>
</thead>
<tbody>
<tr>
<td>U/L</td>
<td></td>
<td></td>
</tr>
<tr>
<td>72-87</td>
<td>0.9916</td>
<td>1.02</td>
</tr>
<tr>
<td>69-92</td>
<td>0.9917</td>
<td>1.50</td>
</tr>
<tr>
<td>62-97</td>
<td>0.9912</td>
<td>1.75</td>
</tr>
<tr>
<td>57-102</td>
<td>0.9008</td>
<td>2.17</td>
</tr>
<tr>
<td>52-107</td>
<td>0.9000</td>
<td>2.66</td>
</tr>
</tbody>
</table>

Reference interval from total data (n = 471): 20-83 U/I.

References

P.P.T.C. News

Tutor Co-ordinator

Michael Lynch, the Tutor Co-ordinator for the P.P.T.C. has taken up a two year assignment with W.H.O. as Development Technical Officer for HIV Testing Services in the Western Pacific. Mike will be based in Manila but as Field Technical Officer will be visiting many Pacific countries to implement laboratory Testing Methods for HIV.

Gilbert Rose has been appointed Tutor Co-ordinator for two years in Mike's absence. Gilbert, formerly the Charge Technologist, Microbiology Department, Christchurch Hospital, has just completed a three year contract as Technical Research Officer with the Papua New Guinea Institute of Medical Research. Gilbert was based in Tari in the Eastern Highlands. In addition to his involvement with research projects Gilbert worked in the Microbiology Laboratory of Tari Hospital.

1989 Programme P.P.T.C.

The P.P.T.C. has undertaken on behalf of the New Zealand Government to assist Western Samoa with the development of a 3 year Technical Training Programme for Medical Laboratory Technologists in Western Samoa.

February — May 1989
The first few months of 1989 will be spent on planning and implementing the first stages of the course in Western Samoa as well as firmly establishing and further developing the Quality Control (QC) Programme for Pacific Island Countries. The QC programme will cover Biochemistry, haematology and Microbiology.

22nd May — 11th August
Immunohaematology Course — P.P.T.C.

11th September — 1st December
Microbiology Course — P.P.T.C.


The Centre is now into its seventh year of activity and this, like the others, is proving to be one of continued progress and development. New activities have included the successful introduction of a course on the sexually transmitted diseases. This course of six trainees included two medically qualified WHO fellows who attended from the Lao People's Democratic Republic. In addition to this, the Pacific Island Quality Assurance Programme was expanded to include Clinical Chemistry. The Management Committee of the P.P.T.C. would like to take this opportunity to thank Ms. Claire Murphy for her major role in introducing this new component to the Programme.

During the 1987/88 year, twenty eight trainees from a range of Pacific Island countries attended courses at the P.P.T.C. In addition to the courses in Haematology/Blood Bank Technology, Sexually Transmitted Diseases and Medical Microbiology, specialised training was provided in Blood Bank Management and HIV testing for two trainees from Fiji. These two special training projects were made possible by the generosity of the Norman Kirk Memorial Trust.

That the Centre has completed another successful year is due in large measure to many individuals and organisations who have given generously of knowledge, training skills and financial assistance. To all, the Management Committee of the Centre express sincere thanks. Following the decision at the last Annual General Meeting to appoint a part-time technologist to assist Mr. Lynch (Tutor Co-ordinator), with the extra work load generated by the introduction of a new course and the expanded Quality Assurance Programme, Mrs Christine Story was appointed in May of this year. Mrs Story's contribution to the work of the Centre has been most valuable and greatly appreciated.

Special thanks are extended to the Wellington Hospital Board for the use of the teaching laboratory area and for the on-campus accommodation facilities for the trainees. It is only through the use of these key facilities that the Training Centre can operate and this major contribution by the board is greatly appreciated not only by the P.P.T.C. but also by the many Pacific Island hospitals who have sent trainees to Wellington over the past seven years.

Thanks are once again extended to the Ministry of Foreign Affairs for the aid grant which enables the Centre to function, and to the Executive and Project Officers of the External Aid Division for valued assistance and guidance.

Central to the activities of the Centre are a continuing flow of suitable trainees, and to achieve this requires the help and co-operation of a number of organisations. Included in these are the Western Pacific Regional Office of the World Health Organisation and the International Division of the New Zealand Department of Health. To the officers of both these organisations for their co-ordinated efforts in assisting the Centre, sincere thanks are extended.

This year, as in the past, we record our indebtedness to the New Zealand Red Cross Society for the Health Science Scholarships which enable trainees to attend Courses at the Centre, and for the increasing administrative and logistical support which comes so cheerfully from the National Headquarters Staff and assists so greatly in the smooth running of the Centre's affairs.

Gilbert Rose — The new Tutor Co-ordinator, P.P.T.C. Don't they wear lab coats in Tari?
The continued support of the New Zealand Institute of Medical Laboratory Technology has been greatly valued during 1987/88, particularly in regard to continued assistance with the quality assurance programme for the clinical laboratories of the Pacific Islands. Thanks are due also to numerous members of the Institute for their effort and time they have taken in locating and sending useful items of equipment to the Centre for use in the teaching laboratory. As in previous years where items of equipment have been duplicated or not required, the Centre, with the assistance of Red Cross, has sent them on to Pacific Island laboratories where a known need exists.

The Centre would like to take the opportunity in presenting this report to acknowledge with thanks the continued interest and generosity of the Wellington Rotary Club in the work of the Centre. The funding of automated pipettes and a bench top centrifuge for use in the Sexually Transmitted Disease Course was greatly appreciated and made a substantial contribution to the successful introduction of that course. In relation to the above course the Committee of the Centre record sincere thanks to Dr Martin Tobias and Staff of the National Haemoglobinics for their valued input.

We are indebted also to the New Zealand Association of Clinical Biochemists for both financial and technical assistance in getting the clinical chemistry component of the Pacific Island Quality Assurance Programme under way and look forward to receiving their much valued help in the future.

In conclusion, sincere thanks are expressed to Mr Michael Lynch, Tutor Co-ordinator of the Centre. Mr Lynch’s efforts within the lecture room and teaching laboratory have once again earned the appreciation of the Committee and trainees for a job well done. To all the staff in the Department of Laboratory Services at Wellington Hospital who gave so generously of their own free time and technical expertise during the past year, the Committee extend sincere thanks.

**Trainees Who Completed Courses At The Pacific Paramedical Training Centre, September 1987 — November 1988**

Kesler Lakutuk (WHO Fellow), Kosrae, Sept-Nov 1987
Medical Microbiology; Tekaibeti Tarataake (WHO Fellow), Kiribati, Sept-Nov 1987
Medical Microbiology; Satlis Chand (NZ Red Cross), Fiji, Sept-Nov 1987
Medical Microbiology; Futalea Lateisi (NZ Overseas Development Aid), Tuvalu, Sept-Nov 1987
Medical Microbiology; Geoffrey Wuatai (NZ Overseas Development Aid), Cook Islands, Sept-Nov 1987
Medical Microbiology; Mason Aotala (NZ Overseas Development Aid), Solomon Islands, Sept-Nov 1987
Medical Microbiology; Milsa Nicholas (NZ Overseas Development Aid), Niue, Sept-Nov 1987
Medical Microbiology; Mohammed Iqbal (Norman Kirk Memorial Trust), Fiji, Feb-Apr 1988
Haematology/Blood Bank Technology; Peia Beu, (NZ Overseas Development Aid), Cook Islands, Feb-Apr 1989
Haematology/Blood Bank Technology; Foliaki Sosene (NZ Overseas Development Aid), Cook Islands, Feb-Apr 1989
Haematology/Blood Bank Technology, Tala Mauala (NZ Overseas Development Aid), Western Samoa, Feb-Apr 1988
Haematology/Blood Bank Technology; Bennie Otoe (NZ Overseas Development Aid), Papua New Guinea, Feb-Apr 1988
Haematology/Blood Bank Technology; Dr Traykhouane (WHO Fellow), Lao People’s Democratic Republic, June-Jul 1988 Sexually Transmitted Diseases Course; Dr Te Thammawong (WHO Fellow), Lao People’s Democratic Republic, Jun-Jul 1988 Sexually Transmitted Diseases Course; Ngatoroka Teaniki (NZ Overseas Development Aid), Cook Islands, Jun-Jul 1988 Sexually Transmitted Diseases Course; Bennie Otoe (NZ Overseas Development Aid), Papua New Guinea, Jun-Jul 1988 Sexually Transmitted Diseases Course; Feitauo Tavai (NZ Overseas Development Aid), Western Samoa, Jun-Jul 1988 Sexually Transmitted Diseases Course; Naibuka Nakabuniceva (NZ Red Cross), Fiji, Feb-Mch 1988 AIDS Laboratory Diagnostic Methods; Jane Tyler (Norman Kirk Memorial Fund), Fiji, Apr-May 1988 Blood Bank Management, Aneta Aritiera (NZ Overseas Development Aid), since May 1982. Extended Training Supervision; Resitara Mataumomai (NZ Overseas Development Aid), Western Samoa, Sep-Nov 1988 Medical Microbiology; Fred Fatale (NZ Overseas Development Aid), Solomon Islands, Sep-Nov 1988 Medical Microbiology; Matanornoa Nicholas (NZ Overseas Development Aid), Cook Islands, Sep-Nov 1988 Medical Microbiology; Reiliko James, (WHO Fellow), Taku, Sep-Nov 1988 Medical Microbiology; Lucy Dibay (WHO Fellow), Yap, Sep-Nov 1988, Medical Microbiology; Mattina Whitney (WHO Fellow), Marshall Islands, Sep-Nov 1988 Medical Microbiology; Tako Tono (NZ Overseas Development Aid), Tonga, Sep-Nov 1988 Medical Microbiology.

**P.P.T.C. — Facilities And Equipment**

The major items of equipment in the teaching laboratory remain in good working order with the exception of one of the older model 37°C incubators which has now passed the stage of further repair and will require replacement in the near future. The generous gift of automatic pipettes and a clinical centrifuge by the Rotary Club of Wellington were most welcome and have proved invaluable. Apart from minor maintenance requirements, no problems of any note were encountered during the past year and the facilities and equipment remain very satisfactory overall.

Items of equipment and disposables donated to the Centre and surplus to our requirements were sent to Pacific Island Laboratories who were in need. On this basis, equipment including centrifuges, a flame photometer, petri dishes, culture media and antisera have been sent to Western Samoa, Tuvalu and Fiji. This service by the P.P.T.C. is greatly appreciated by many of the small Pacific Island Medical Laboratories who function on tight budgets and have difficulties in replacing work out equipment.

**Visitors To The P.P.T.C.**

Visitors were received during the year from the Red Cross Society, the Department of Health and Service Clubs. On occasions, visitors from these organisations have had overseas visitors with them who were involved in technical training programmes for developing countries and for this reason were interested in the teaching strategies developed by the P.P.T.C.

Visitors of note include Ms Elizabeth Williams, Assistant Director Training, Ministry of Foreign Affairs, Mr Alan Oaisa, High Commissioner for Papua New Guinea, Dr John Jewsbury, from the Liverpool School of Tropical Medicine, and external examiner in Parasitology for the Fiji School of Medicine, Dr Helen Bichan, Acting Chief Medical Officer, Wellington Hospital and Sir Paul Reeves, Governor General of New Zealand.
INSTITUTE BUSINESS

President
W.J. Wilson
Auckland Regional Blood Centre

Vice-Presidents
D. Dixon-McVyer
P. McLeod

Secretary
B. T. Edwards
Haematology, Christchurch Hospital

Treasurer
D. M. Reilly
Diagnostic Laboratory, Auckland

Council
E. Norman, S. Gainsford, J. Parker, J. Le Grice, G. Rimmer

Editor
D. Dixon-McVyer
Biochemistry Dept., National Women’s Hospital, Auckland; or the Editor, P.O. Box 35-276, Auckland, 10.

Membership Convener
Geoff Rimmer
P.O. Box 29-115, Greenwoods Cnr, Auckland.

Membership Fees and Enquiries
Membership fees for the year beginning April 1, 1989 are:
For Fellows — $104.00 GST inclusive
For Associates — $104.00 GST inclusive
For Members — $52.00 GST inclusive
For Non-practising Members — $33.00 GST inclusive

All membership fees, changes of address or particulars, applications for membership or changes in status should be sent to the Membership Convener at the address given above.

Members wishing to receive their publications by airmail should contact the Editor to make the necessary arrangement.

Membership Sub-Committee Report
March 1989

Since the October meeting there has been the following changes:

<table>
<thead>
<tr>
<th></th>
<th>17.3.89</th>
<th>22.2.89</th>
<th>12.10.88</th>
<th>31.8.88</th>
</tr>
</thead>
<tbody>
<tr>
<td>Membership</td>
<td>1699</td>
<td>1623</td>
<td>1553</td>
<td>1499</td>
</tr>
<tr>
<td>less resignations</td>
<td>4</td>
<td>11</td>
<td>3</td>
<td>8</td>
</tr>
<tr>
<td>less G.N.A.</td>
<td>—</td>
<td>15</td>
<td>—</td>
<td>14</td>
</tr>
<tr>
<td>less deletions</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>less deceased</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>plus applications</td>
<td>14</td>
<td>102</td>
<td>73</td>
<td>77</td>
</tr>
<tr>
<td>plus reinstatements</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Total</td>
<td>1709</td>
<td>1699</td>
<td>1623</td>
<td>1553</td>
</tr>
</tbody>
</table>

Applications for Associateship:
EXTON, Katherine, Auckland; McCOMB, Penelope, Auckland; FINDON, Glenne, Auckland; HOSKEN, Leigh, Auckland; POLOAI, James, Auckland; WOODS, Gillian, Auckland; MASON, Elizabeth, Auckland; JOHNSTON, Yvonne, Auckland; BROOKING, Judith, Auckland; TAYLOR, Faith, Auckland; MAYES, Neil, Auckland; HUMPHREY, Myra, Auckland; JONES, John, Auckland; PAPERA, Ina, Kawakawa; HOLLOWAY, Russell, Auckland; CAMPBELL, Anna, Auckland; TOY, Gail, Auckland; MURPHY, Deborah, Auckland; HAINES, David, Auckland; EDWARDS, Philippa, Gisborne; SMITH, Murray, Tauranga; PAYNE, Gordon, Tauranga; PETERS, Jennifer, Gisborne; McPHERSON, Lois, Auckland; WHITE, Glennis, Wellington; ANDERSON, Margaret, Wanganui; MacKAY, John, Wanganui; LOCKERY, Alan, Hastings; KERR, Alistair, Palmerston North; BELL, Robyn, Dunedin; MacDONALD, Elizabeth, Gore.

Applications for Membership:
COWLEY, Norma, Auckland; TETAI, Reremoana, Auckland; PATEL, Mansukh, Auckland; TIPENE, Lilian, Kawakawa; HUNTER, Ian, Auckland; VASS, Alison, Auckland; SEATH, Verena, Kawakawa; TORRIE, Julie, Auckland; WRIGHT, Jackie, Auckland; COUPER, Anne, Auckland; TATE, Gina, Auckland; PRASAD, Kamala, Auckland; MOUNTFORD, Louise, Auckland; ARCHER, Robyn, Auckland; GOUNDER, Pushpa, Auckland; BALLARD, Lynda, Auckland; AIRD, Megan, Auckland; WARDEN, Mark, Auckland; STANLEY, Karen, Auckland; SELMAN, Gillian, Auckland; BAILEY, Alison, Auckland; JULL, Tessa, Auckland; HANRAHAN, Vickie, Whangarei; ADLINGTON, Janet, Auckland; MCCONNOCHIE, Evelyn, Auckland; TAUAT, Nicky, Auckland; KIERNAN, Michelle, Auckland; GLAVAS, Christine, Auckland; GILBY, Gaylene, Auckland; SIMPSON, Wendy, Auckland; WALL, Alexandria, Auckland; POWELL, Johnathan, Auckland; MCCREWDY, Wendy, Auckland; REECE, Tracey-Maree, Auckland; BRADBURN, Nicola, Auckland; COOK, Lynne, Auckland; PRIDDE, Terrence, Auckland; STIMPSON, Vicki, Gisborne; ROSS, Sarah, Waikato; OAKLEY, Alison, Waikato; ELGAR, Penela, Rotorua; PAGE, Nicholas, Rotorua; PARKINSON, Christine, Rotorua; FUNNELL, Alison, Gisborne; STOPFORD, Ronceville, Gisborne; LIBEAU, Delwyn, Hamilton; HAMPTON, Gleris, Mt Maunganui; BROWN, Shirley, Hamilton; POWELL, Kathryn, Hamilton; MOOL, Julie, Hamilton; FLACK, Christine, Palmerston North; ADAM, Sandra, Waiukuera; PRONK, Marcel, Hastings; STILL, Lee-An, Hutt; GOSS, Michelle, Hutt; MCKINNON, Jane, Palmerston North; MAITLAND, Carla, Palmerston North; SMALL, Michael, Wanganui; DORAN, Stephanie, Wanganui; HOLDER, Kathryn, Palmerston North; FITZSIMONS, Glynnis, Felding; HOLLIE, Maxine, Hutt; FROGGATT, Vivienne, Wellington; ANDERSON, Carmen, Napier; hOLOWAY, Christina, Palmerston North; WEARNE, Kim, Wellington; BILLETT, Susan, Napier; BLAKE, Tareleigh, Wairoa; WESTNEY, Penny, Christchurch; MCKENDRY, Sara, Christchurch; PIKE, Linda, Christchurch; JEFFERY, Nadine, Dunedin; DAVIES, Janet, Dunedin; VOICE, Lee-Ann, Christchurch; GRACZIK, Sandra, Christchurch; MURRAY, Elizabeth, Christchurch; DUNLOP, Carol, Christchurch; RICKETTS, Angela, Christchurch; MOIR, Carolyn, Invercargill; AVIS, Karen, Dunedin; CROKER, Deborah, Dunedin; LAU, Siong Kiew Peter, Sarawak, Malaysia.

Applications for Non-Practising Membership:
HALL, Faye, Wellington; MILLER, Euan, Auckland.

Resignations:
WHITTAKER, ANDREW. D.J.; GONE NO ADDRESS: FINCH, LETTERS CALEY, ROBERTSON, NORRIS.

Yours to go overseas again, and that is why Badhusvagen 2
Inger

a. and some

taking overseas and work. I worked as a Lab. Tech. in a Laboratory Sciences in December 1981 and have since then finished the

months working as a Lab. Tech. for the lab also takes over the bloodbanking duties.

Last year I spent 7½ months working as a Lab. Tech. for the UN in south Lebanon. Now I'm back in Sweden but I'm dying to go overseas again, and that is why I'm writing to you. If you have any work for a 26 years old girl from Sweden please contact me and I will send you my personal record.

Yours sincerely,
Inger Pettersson
Badhusvägen 2
460 20 Sjuntorp, Sweden.
Tel. 0520-40798.

NEW PRODUCTS AND SERVICES

WELLCOLEX — THE WINNING COMBINATION FOR SALMONELLA TESTING

WELLCOLEX Colour Salmonella, the new latex test for Salmonella from Wellcome Diagnostics, combines colour and speed in the race for faster Salmonella results.

WELLCOLEX Colour Salmonella is a unique colour latex test incorporating red, blue and green latex particles sensitised with antibodies to different Salmonella groups giving group identification in single test. This is the only colour latex test for Salmonella able to distinguish between different Salmonella groups and giving results as early as day two, reducing by up to two days the time required by current methodologies. WELLCOLEX can, therefore, save both laboratory time and costs with less time wasted on negative smaples.

WELLCOLEX also offers the advantage of increased confidence in Salmonella testing with sensitivity of 99.8 per cent and specificity of 99.2 per cent. The easy to follow protocol minimises hands-on time and novel latex technology enhances readability of the final result.

Each kit contains sufficient materials for 50 tests and a reaction card showing examples of colour latex agglutination patterns is provided for reference.

For further information contact: Wellcome New Zealand Limited, P.O. Box 22-258, Otahuhu, AUCKLAND. Tel: (09) 276-1788.


Gone No Address:

LETTERS TO THE EDITOR

Dear Sir,

re: A position in a New Zealand Laboratory

I am a Swedish Laboratory Technician who would like to go overseas and work. I finished the School of Medical Laboratory Sciences in December 1981 and have since then worked as a Lab. Tech. in a Clinical Chemistry Laboratory.

My duties consist of ordinary Lab. Tech. work such as taking blood-tests and analyzing them. The kind of tests we carry out are all the haematological tests, biochemistry tests and some immunological tests such as Hepatitis virus, HIV a.b. and Rubella a.b. During evenings, nights and weekends the lab also takes over the bloodbanking duties.

Last year I spent 7½ months working as a Lab. Tech. for the UN in south Lebanon. Now I'm back in Sweden but I'm dying to go overseas again, and that is why I'm writing to you.

If you have any work for a 26 years old girl from Sweden please contact me and I will send you my personal record.

Yours sincerely,
Inger Pettersson
Badhusvägen 2
460 20 Sjuntorp, Sweden.
Tel. 0520-40798.

TSH TESTING IS AS EASY AS 1 2 3

1 Add sample, calibrator or control.
2 Add tracer and shake.
3 Decant, wash and count

We dare you to compare the all NEW DPC Coat-A-Count TSH IRMA Kit. Compare our ease of use and sensitivity, then compare our price. YOU will like what YOU find.

Distributed By:
Med-Bio Enterprises Ltd
P. O. Box 33-135 P. O. Box 13-595
Christchurch Auckland
Phone (03) 381-020 Phone (09) 655-912
THE FUTURE OF BLOOD GAS

NOVA Stat Profile analyzers have rewritten the standards for modern blood gas instrumentation.

Blood Gases, Electrolytes, Hematocrit, Glucose and Osmolality, combined in test selective analyzers

NOVA's series of Stat Profile analyzers introduce the most fundamental technical advances in blood gas instrumentation in thirty years. These advances include:

- Test menus that include pH, PCO₂, PO₂, Na⁺, K⁺, Glucose, Ca²⁺, Cl⁻, and Hct measurements.
- Test selectively within an instrument's test menu so it is not necessary to run all tests on all samples.
- Models that can be upgraded in the laboratory if the instrument has less than the full test menu.
- Sample analyses performed at a rate of 38 samples per hour (all nine parameters), a speed two times that of today's blood gas analyzers.
- A sample volume for the full nine parameter profile of only 250 microlitres of whole blood.
- Instrument problem diagnosis electronically via a telephone/computer interface (modem) linked directly to the technical service centre.

Data Management System
New Available As Optional Extra.
Q.C., Patient Data, Billing
The Wellcozyme range of diagnostic products is continually updated so you can protect the community more effectively.

Our tests for HIV antibody, Hepatitis B Markers, Herpes Simplex Virus and Rotavirus give you fast, accurate results.

And now, our HIV Recombinant test is a further step forward in diagnostic technology.

Contact your local supplier for further information.
Innovative Methodology

Angiotensin Converting Enzyme
ATP Bioluminescence CL5
ATP Bioluminescence H5
Apolipoprotein A1
Apolipoprotein A2
Apolipoprotein B
2,3-Diphosphoglycerate
Endoproteinases
Fibronectin (Opsonic protein)
Free Fatty Acids
Fructosamine
N-Acetyl-B-D-Glucosaminidase
NAD (P)H bioluminescence
Protein C-activation set
Sialic acid
T-cell ELISA
Free Cholesterol
Galactose
GLDH act
Lactate

Pynuvate
LDH isoenzymes
LDL Cholesterol
Lecithin
Pancreatic a-amylase
Pyruvate Kinase
Triglycerides W/O glycerol
ASLC Tinaquant
Ferritin Tinaquant
RF Tinaquant
Cholinesterase
Transferrin Tinaquant
Coagulation
Prolactin
Oxalate
Citric Acid
Ascorbic Acid
Fructose
Non-radioactive DNA labelling
and detection system